Search clinical trials for: ingenol mebutate 0.05% gel

Total 160 results

LEO Pharma

Completed

A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

Actinic Keratosis

Italy
Korea University
Samsung Medical Center; Asan Medical Center; Chonnam National University Hospital and other collaborators

Completed

Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis

Actinic Keratosis

Korea, Republic of
LEO Pharma

Completed

Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%

Actinic Keratosis

Australia, Germany
LEO Pharma

Completed

PMS to Evaluate the Safety and Efficacy of Picato® Gel

Actinic Keratosis

Korea, Republic of
Peplin

Completed

A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis

Actinic Keratosis

United States
Neal D. Bhatia, MD
LEO Pharma

Completed

Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

Verruca Vulgaris | Common Warts

United States
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

Actinic Keratosis

Germany
University of California, San Francisco

Completed

Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients

Actinic Keratosis

United States
Peplin

Completed

A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Actinic Keratosis

United States, Australia
Skin Laser & Surgery Specialists
LEO Pharma

Completed

Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin

Actinic Keratosis | Photo-aged Skin
Peplin

Completed

PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities

Superficial Basal Cell Carcinoma

Australia
Peplin

Completed

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Actinic Keratoses

United States
Peplin

Completed

A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

Actinic Keratosis

United States
Peplin

Completed

Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin

Photo-damage

Australia
Icahn School of Medicine at Mount Sinai
LEO Pharma

Completed

Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

Actinic Keratosis

United States
LEO Pharma

Completed

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

Actinic Keratosis

United States
Instituto Nacional de Cancer, Brazil

Withdrawn

Evaluation of Ingenol Mebutate for Actinic Cheilitis Treatment (EIMAC)

Actinic Cheilitis
Peplin

Completed

A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

Actinic Keratosis

United States
Peplin

Completed

Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis

Seborrheic Keratosis

Australia
Peplin

Completed

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Actinic Keratoses

United States, Australia
LEO Pharma

Completed

Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

Actinic Keratosis

Canada, Germany, Australia, France, United Kingdom
Icahn School of Medicine at Mount Sinai
LEO Pharma

Completed

Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses

Actinic Keratoses

United States
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy

Actinic Keratosis

Germany
Padagis LLC

Completed

To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis

Actinic Keratosis
LEO Pharma

Completed

Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm

Actinic Keratosis

Australia
Goldman, Butterwick, Fitzpatrick and Groff
LEO Pharma

Completed

Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%

Actinic Keratosis

United States
Padagis LLC

Completed

To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis

Actinic Keratosis
Icahn School of Medicine at Mount Sinai
LEO Pharma

Completed

Treatment of Actinic Keratoses (AK) on the Face

Actinic Keratoses

United States
Eisai Limited

Completed

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions

Actinic Keratosis

United States
Actavis Inc.

Completed

A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis

Actinic Keratosis

United States
Northwestern University

Withdrawn

Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions

Actinic Keratosis
LEO Pharma

Completed

The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice (PrAKtice)

Actinic Keratosis

Greece
Actavis Inc.

Completed

An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

ACTINIC KERATOSIS

United States
LEO Pharma

Completed

TreatMent of ActInic KerAtosis Lesions : pharmacoepiDemiological Study of the Impact in Real Life of ingenOl Mebutate Gel (Picato®) on Patients Satisfaction (MIKADO)

Actinic Keratosis
LEO Pharma

Completed

Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Actinic Keratosis

United States
LEO Pharma

Completed

Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest

Actinic Keratosis

United States
LEO Pharma

Completed

Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks

Actinic Keratosis

Germany
Merete Haedersdal
LEO Pharma

Completed

Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate

Carcinoma, Basal Cell

Denmark
University of Campania "Luigi Vanvitelli"

Completed

Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy

Actinic Keratosis

Italy
LEO Pharma

Completed

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

Actinic Keratosis

United States
Pacific Dermaesthetics
LEO Pharma

Unknown

Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis

Actinic Keratosis
Günther Hofbauer

Terminated

Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses (IMOT001)

Actinic Keratosis

Switzerland
LEO Pharma

Completed

Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%

Actinic Keratosis (AK)

Germany, United Kingdom, France
LEO Pharma

Terminated

A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp

Actinic Keratosis | Squamous Cell Carcinoma

United States, Spain, Canada, Germany, France, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Actinic Keratosis

Germany
University of Sao Paulo
LEO Pharma

Completed

Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis

Actinic Keratosis

Brazil
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp

Actinic Keratosis (AK)

Germany
Centre Hospitalier Universitaire de Nice

Completed

Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma (PICABAS)

Carcinoma

France

3

Subscribe